Skip to main content

Table 3 Visual acuity and macular thickness measurements

From: Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study

 

Treatment group (sirolimus + aflibercept)

Control group (aflibercept monotherapy)

p-value

BCVA Change (ETRDS Letters)

2.5

0.8

0.42

Central Subfield Thickness (μm)

− 54.0

− 0.1

0.28

Subretinal Fluid (N)

9

9

SRF Change (mm3)

− 9.32

− 3.02

0.54

Intraretinal Fluid (N)

4

4

 –

IRF Change (mm3)

− 0.43

− 0.99

0.60

Corrected IRF Change (mm3) a

− 1.02

− 2.48

0.59

Central 1 mm (N)

10

10

Foveal Change (mm3)

− 0.49

− 0.66

0.78

  1. aSubjects who did not have intraretinal fluid during the course of the study were excluded from this calculation to gain a better appreciation of the true change in IRF